Embedded Files
Keep up to date with all of the latest research news, events and project updates from the UK MND Research Institute
News archive
News archive
MHRA approves tofersen for treatment of SOD1-MND
MHRA approves tofersen for treatment of SOD1-MND
31st July 2025
The Medicines and Healthcare products Regulatory Agency (MHRA) has approved the use of tofersen, the first licensed treatment in the UK for motor neuron disease (MND) caused by a variation in the SOD1 gene. Read more here.
MIROCALS study results published
MIROCALS study results published
15th May 2025
Results from MIROCALS, a phase 2 trial of low-dose interleukin 2 (IL-2LD), have been published in The Lancet. The UK MND Clinical Studies Group has written a statement to support clinical teams, patients and the public to interpret the results and outline what we believe the next steps forward will be. You can view the statement here.
Letter to NICE in response to the decision regarding Tofersen
Letter to NICE in response to the decision regarding Tofersen
20 March 2024
The UK MND Clinical Studies Group has written to the National Institute for Health and Care Excellence (NICE), expressing concern over the decision to appraise the drug Tofersen through the Single Technology Appraisal route, and the implications this will have for people living with motor neuron disease in the UK. You can read the letter here
Page updated
Report abuse